Exclusive patented technology: WNE® 3-
position pneumatic actuator

Simplicity for ultimate reliability

ORA’s exclusive patented WNE® 3-position pneumatic actuator guarantees the smooth and reliable transfer of fluids and increases the options for developing sequence steps in a recipe whilst potentially also decreasing overall synthesis times. Compared to traditional 2-position pneumatic actuators, the 3-position pneumatic actuator technology guarantees accurate positioning at every turn. Only pneumatic pressure is required for their operation.

However, most of all it provides reliability against radiation damage by uniquely using compressed air. In a radioactive environment, long term reliability of components is essential. Standard electrically driven actuator systems are susceptible to radiation damage due to the need for an electronic logic control system.

The patented WNE®️ system is now used as standard in the new range of NEPTIS®️ synthesizers: NEPTIS®️ Perform, NEPTIS®️ RS, NEPTIS®️ DB, NEPTIS®️ LC and NEPTIS®️ xSeed™️.

ora neptis wne system
ora neptis synthesizer and actuators

xSeed Manifold

The WNE® 3-positions actuators were also modified for the development of the NEPTIS® xSeed, automated kit-less module. The disposable rotating valves are replaced with fixed 3-positions valves that are resistant to all chemicals and rinsible between each run. Thanks to these characteristics, NEPTIS® xSeed is a true multi-run system, it will quicken the research and development phases of new radiopharmaceuticals.

ora neptis synthesizer cassette

QMA recycling

This invention relates to a method of performing a plurality of synthesis processes for preparing a radiopharmaceutical in series, the method comprises of carrying out a first synthesis run involving the following steps:

  1. Providing water containing [18F]fluoride
  2. Trapping the [18F]fluoride from the water provided on an anion exchange material
  3. Eluting the trapped [18F]fluoride from the anion exchange to a reaction vessel
  4. Preparing a radiopharmaceutical incorporating the eluted [18F]fluoride
  5. This method comprises of a reconditioning anion exchange step between two consecutive runs




The Modular 01 project involves the development of a new generation of synthesizers dedicated to the production of radiopharmaceuticals used in diagnosis (tracers) or in therapy.

The system consists of different sub-modules for radioisotope management, the labelling step, post-labelling chemistries and the final purification/formulation. These sub-modules can be used independently, all together or in combination, and have the ability to self-clean.

Improvements in inert volumes, resistance to radioactivity, reactor size, chemical sampling, management of chemical and radioactive waste as well as optimization of reaction parameters are necessary improvements to reduce drug development time.

The validation of the system for pharmaceutical production and according to the ISO13485 standard on medical devices will also provide necessary documentation on the module so that the pharmaceutical files can be created much faster for submission to the regulatory authorities.

The device will improve the screening of compounds in research and development laboratories and their transfer to pharmaceutical production. It will also be weaned from its dependence on exclusive consumables which is the main bottleneck in the development of a radiopharmaceutical drug.



ora neptis partners

Coopilot / Mecatech / Feder

The overall objective of the Spinner project is to develop a fully automated system to achieve the development, monitoring and scaling up of new chemical reactions and processes while respecting the fundamentals of green chemistry.

This reactor makes it possible to reduce the volumes of organic solvents used, which in turn improves the energy efficiency of reactions as well as process safety.

This system will be fully automated, allowing full control of the reaction parameters (speed of rotation, temperature, addition of reagents, sampling for analysis), post-processing as well as cleaning of the reactor. This will enhance the reproducibility of results and allow Research and Development teams to free themselves from repetitive, time consuming tasks in order to devote more time to strategic innovation.